Teradyne, Inc.

Cash generation is recovering rapidly alongside the semiconductor test cycle inflection. In FY2025, operating cash flow was $674,415,000 and free cash flow reached $450,406,000 after capital expenditures of $224,009,000. In Q2 2026, operating cash flow reached $469,138,000, bringing six-month operating cash flow to $734,262,000. Working capital expansion has absorbed cash to finance elevated accounts receivable ($1,109,711,000 as of June 28, 2026) as tester deliveries accelerate, but underlying cash conversion remains healthy.^5,6

Teradyne maintains a disciplined capital allocation strategy focused on internal reinvestment, bolt-on acquisitions, share repurchases, and regular dividends. In the first six months of 2026, the company deployed $155,439,000 into , $165,611,000 into business acquisitions, $74,238,000 into repurchases, and $40,710,000 into dividend distributions ($0.13 per share quarterly, $0.26 per share YTD). Balance sheet cash and equivalents totaled $349,538,000 as of June 28, 2026, with zero .

Return on invested capital is expanding rapidly during the current cyclical inflection, supported by Q2 2026 operating income of $437,810,000 compared to FY2025 operating income of $650,051,000 on invested capital of $2,995,752,000. Operating efficiency over installed capital assets confirms high returns on incremental capital.

Teradyne's ROIC comfortably exceeds both its moderate cost of equity of 11.68% and its strict cost of capital of 12.69%, demonstrating strong economic value creation despite severe stock price overvaluation.

Semiconductor Test delivered $2,523,744,000 (79.1% of revenue) in FY2025 and surged to $1,122M (84.4% of revenue) in Q2 2026.

Operating leverage is intense; non-GAAP expanded to 33.7% in Q2 2026 from 20.38% in FY2025, yet profitability remains highly vulnerable to any downcycle in semiconductor test tool spending.

The bull cycle is propelled by structural packaging complexity in artificial intelligence silicon, multi-die chiplets, and high-bandwidth memory (HBM), which significantly lengthens test times and raises test equipment spending from 4% of semiconductor capex in 2023 to 8% in 2026. As foundry advanced packaging lines ramp up and memory customers add test cells into 2027, automated test equipment TAM expands toward management's long-term target of $20 billion by the end of the decade.

The bear cycle emerges when semiconductor capital expenditure buildouts in high-performance compute and HBM reach capacity saturation, prompting hyperscalers and chipmakers to enter an order digestion phase. Management has warned that test intensity as a percentage of semiconductor capex could mean-revert from 8% in 2026 back to 6%-7% in 2027. A simultaneous reduction in wafer equipment spending and test intensity would cause back-end automated test equipment bookings to contract sharply, compressing margins toward historical trough levels.

Risk management mandates strict capital preservation given the 79.5% premium to Fair value. Teradyne's high raw beta of 1.7944 signals substantial drawdown vulnerability during market corrections. Portfolio managers should avoid call option writing that entails delivery obligations and eliminate equity long exposure.